Anzeige
Mehr »
Login
Samstag, 05.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Eine goldene Gelegenheit in Kupfer: Warum Gladiator Metals eine Top-Wahl für 2024 sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
575 Leser
Artikel bewerten:
(2)

Songtradr: SONGTRADR EXPANDS ITS B2B MUSIC TECHNOLOGY SOLUTIONS - ACQUIRES LEADING ADVANCED AI SEARCH COMPANY, MUSICUBE

The Hamburg-based AI technology company enables measurable ROI-driven licensing that optimizes the creative performance of content

LOS ANGELES, June 7, 2022 /PRNewswire/ -- Songtradr, the world's leading B2B music company, announced today the acquisition of leading AI metadata and music search company, Musicube. The transaction expands the company's portfolio of tech-enabled music solutions designed to license the right music for any content, driving higher ROI and enabling brands to measurably engage their target audience. Using neural networks and proprietary artificial intelligence, Musicube's semantic search has reached product leadership in both quality and data depth. It helps match music to content and a brand's target audience. This technology further enhances Songtradr's B2B music solutions that harness the power of data and tech-enabled intelligence with creative excellence.

Songtradr Logo

"Musicube has approached audio analysis from an entirely unique perspective and this acquisition accelerates our mission to increase the value and effectiveness of music in content," said Paul Wiltshire, CEO of Songtradr. "Their impressive team of passionate musicologists and data scientists understand the power of data and its relationship with music, which ultimately benefits our brand and agency customers as well as music rights holders. In order to have the world's best B2B music search and recommendation technology, we need premier metadata enrichment technology, which is a key component of the B2B music supply chain. Adding the Musicube technologies, data and extraordinary team to Songtradr will help accelerate our enterprise customer user experience."

Musicube's proprietary software is delivered via web widgets and an API that provides pristine metadata at scale for music labels, publishers, music supervisors, among many other audiences. The technology also enables customers to search for tracks, playlists and artists based on audiences, moods, genres, vocal features, instruments, tempo and more, unlocking the true value of catalogs and rights.

David Hoga, CEO and founder of Musicube, said: "Songtradr is the most exciting music company we have seen in a very long time. We are incredibly happy to join this exceptional team of music lovers and technologists as every single conversation we have had can be characterized by both cordiality and an ambitious agenda. We share a common vision of an artist-friendly music industry, using data to achieve it."

With a team of more than 350 people and offices in 12 countries worldwide, Songtradr has grown from being a music tech product for independent artists to a multi-disciplined, end-to-end solution for music buyers, brands and rights holders.

Songtradr's unique portfolio of the world's leading music services companies (Massive Music, Big Sync Music and Song Zu) alongside its industry-leading technology and data products (Songtradr, Tunefind, Pretzel, Jaxsta (investment only) and Musicube) provides its customers a distinct advantage to maximize the value of music in their projects.

For more information about Songtradr's products and services, visit songtradr.com.

ABOUT MUSICUBE:

Musicube's music AI solution provides rich metadata for music labels, publishers, rights holders and others seeking song discoverability tools. The database includes more than 50 million song titles with ISRC and all contributors, as well as more than 500 keywords (such as moods, musical characteristics, content from song lyrics and many more). The company is composed of experienced musicologists and data scientists based in Hamburg, Germany. For more information, visit http://www.musicu.be.

ABOUT SONGTRADR:

Songtradr is where music meets data, ideas meet innovation, and brand missions are transformed by sound.

We work with brands, agencies, businesses, labels, artists, and more, empowering them to excel on an international stage. Propelled by technology, real-time data intelligence, and musical expertise, our fully integrated products and services help amplify brands and enable artists and rights holders to realize the full potential of their catalog.

Whether with a classic song or a trending tune, a global music strategy or a sonic identity, we help translate ideas into powerful, ROI-driven solutions to ensure content always hits the right note.

We power the world with music.

Press Contact:
Kara Gaughan
Jive PR + Digital
778-872-7676
kara@jiveprdigital.com
www.jiveprdigital.com

Logo - https://mma.prnewswire.com/media/1832398/Songtradr_Logo.jpg
Logo - https://mma.prnewswire.com/media/1832397/Musicube_Logo.jpg

Musicube Logo
© 2022 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.